Seladelpar is a novel PPAR-δ agonist, indicated for the treatment of adult patients with primary biliary cholangitis (PBC) who have an inadequate response to ursodeoxycholic acid (UDCA) or cannot tolerate UDCA. As a newly approved prescription drug in 2024, it has special requirements for purchase channels, usage precautions, and authenticity identification.

How to Purchase Seladelpar

Overseas Purchase

Patients may choose to consult and purchase the medication at hospital pharmacies or legitimate drugstores in countries or regions where Seladelpar has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase through Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions usually provide legal import channels and can offer professional consultation and guidance.

Precautions for Purchasing Seladelpar

Medical Evaluation Before Medication Use

Liver function test: Obtain baseline clinical and laboratory liver assessment results.

Renal function test: No dose adjustment is required for patients with mild to severe renal impairment.

Bone mineral density assessment: Consider the risk of fractures, especially in patients with existing osteoporosis.

Confirmation of Dosage Form and Specification

Seladelpar is an oral hard capsule.

Specification: 10 mg per capsule; opaque hard gelatin capsule, Size 1, with an opaque light gray capsule body and an opaque dark blue capsule cap.

Appearance: The capsule cap is printed with "CBAY", and the capsule body is printed with "10".

Packaging: It should be the original 75cc high-density polyethylene (HDPE) bottle, equipped with a 38mm polypropylene child-resistant cap and an induction seal.

Notification of Drug Interactions

Strong CYP2C9 inhibitors: Concomitant use is prohibited.

OAT3 inhibitors: Concomitant use is prohibited.

Bile acid sequestrants: Administration should be separated by at least 4 hours.

Rifampicin: Monitor biochemical responses (e.g., ALP and bilirubin).

Methods for Identifying the Authenticity of Seladelpar

Characteristics of Outer Packaging

The packaging bottle is made of 75cc high-density polyethylene (HDPE).

The bottle cap is a 38mm polypropylene child-resistant cap with an induction seal.

The label information is complete and clear, including the manufacturer information of Gilead Sciences.

Characteristics of the Drug Itself

Hard gelatin capsule of Size 1.

Opaque light gray capsule body and opaque dark blue capsule cap.

The capsule cap is printed with "CBAY", and the capsule body is printed with "10".

The contents should be a white to off-white powder.

Verification of Anti-Counterfeiting Markings

Unique batch number and expiration date coding.

Complete drug instruction manual.

Authenticity can be verified through channels provided by the manufacturer.